The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid. Bullous pemphigoid ...

After hours: March 19 at 4:09:31 PM EDT Loading Chart for SNY ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

Regeneron Pharmaceuticals recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing serious ...

“For me, it represents our legacy, it represents the ability, even in the most difficult situations, to come together as a unit and make something work.” ...

[BRIEFING.COM] The S&P 500 (-2.77%) is in second place on Monday afternoon.

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late ...

Quickly spreading erythema, ecchymosis with vesicles enlarging to purple bullae, should immediately alert the nurse to NF. Inside these purple bullae is a foul smelling, thin, watery fluid known ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Red spots on the skin can appear for a variety of reasons, ranging from harmless to potentially serious conditions. They can be caused by simple irritants like dermatitis, infections such as ringworm, ...